Top Stories
The FDA's Office of New Drugs determined that there was "substantial evidence of effectiveness" for ONS-5010 in treating wet age-related macular degeneration.
The Japanese drugmaker said Leqembi is projected to generate JPY 300 billion in annual revenue by fiscal 2028, while the UN's updated action plan has elevated vaccination to a more central pillar for fighting drug-resistant infections.
The two companies have been in discussions about a potential deal that could be weeks away, Bloomberg said.
The company said updated early-stage results for VERVE-102 strengthen case for one-time cholesterol treatment.
The tool could help identify which patients are most likely to benefit from immunotherapy and stem cell transplantation.
Conference News
Cedars-Sinai physician-scientists will share clinical breakthroughs and updates on emerging cancer treatments at the ASCO annual meeting.BYLINE: Christina ElstonNewswise — LOS ANGELES (May 26, 2026) -...
— Company to Present 11 Posters Demonstrating Commitment to Advancing Innovative Research for People Living With Chronic Psychiatric and Neurological Disorders —DUBLIN--(BUSINESS WIRE)-- Alkermes plc ...
Study to evaluate OP-3136, Olema’s novel KAT6 inhibitor, in combination with darolutamide in approximately 36 patients; expected to initiate in H2 2026First clinical collaboration for OP-3136; results...
Single dose of EDIT-401 achieved ~90% or greater mean reductions in LDL-C, Lp(a), and ApoB in non-humanprimatesData reinforce differentiated LDLR upregulation approach with rapid, dose-dependent effec...
Real-world analysis of three years of closed claims data from Symphony Health focused on the third year of the study (2023-2024), comprised of more than 261,000 U.S. adults with fibromyalgiaData under...
